person

Aleksandar Skuban, M.D.

as of 2026-07-01
Monitor thisAsk about this
at a glance
Roles: Study Director
Synthesized from structured facts only — each point cited above.

Profile

Affiliation
Otsuka Pharmaceutical Development & Commercialization, Inc.
Roles
Study Director
Trial investigator
no

Trials led

4
Efficacy Study of OPC-34712 in Adults With Acute Schizophrenia
NCT01393613Phase 3Completed
Safety and Tolerability Study of Oral OPC-34712 as Maintenance Treatment in Adults With Schizophrenia
NCT01397786Phase 3Completed
Study of the Effectiveness of Three Different Doses of OPC-34712 in the Treatment of Adults With Acute Schizophrenia
NCT01396421Phase 3Completed
Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia
NCT01668797Phase 3Completed

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
STUDY_DIRECTOR
Efficacy Study of OPC-34712 in Adults With Acute Schizophrenia
trial
Safety and Tolerability Study of Oral OPC-34712 as Maintenance Treatment in Adults With Schizophrenia
trial
Study of the Effectiveness of Three Different Doses of OPC-34712 in the Treatment of Adults With Acute Schizophrenia
trial
Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia
trial